Study drug for advanced colon cancer that has come back or failed
Part of Cancer, Digestive system clinical trials.
This Phase 1/2 trial tests LYL273, a new targeted treatment, for people with metastatic colorectal (colon) cancer that has returned or not responded to standard chemo. It’s designed to see how well the drug can control the cancer and what side effects it causes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be over 18 years old
- Your colon cancer must be metastatic and either relapsed or refractory (not responding or coming back)
- You should be well enough to do daily activities (performance status 0 or 1)
- Your liver involvement must be limited (fewer than 7 liver lesions and largest under 3 cm)
- You must not have a curative surgery option, and you must have already tried standard chemotherapy (fluoropyrimidine, oxaliplatin, irinotecan)
- You need at least one measurable tumor spot outside the brain that doctors can track on scans
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy and a targeted therapy (cetuximab) as the first treatment for colorectal cancer that has come back or spread. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a new combination of drugs (liposomal irinotecan, 5-FU/LV, and bevacizumab) for people with advanced colorectal cancer that cannot be removed by surgery. The goal is to see if this treatment is safe and effective in shrinking tumors and improving outcomes.
This trial tests a new vaccine (YMN-136) for people with colorectal cancer that has spread to the liver and hasn't responded to at least three prior treatments. The goal is to see if the vaccine can help control the cancer.
This study tests a new combination of three drugs for advanced colorectal cancer that has not responded to standard treatments. The goal is to see if this combination can shrink tumors or slow down the cancer's growth.
This Phase 2 study tests the best way to choose and then follow treatment when colorectal cancer has spread only to a small number of spots. You may be eligible if your doctors can remove or precisely treat the spots and there’s no sign of additional spread on scans.
This Phase 3 trial studies a treatment approach for people whose colorectal cancer has come back in the liver within 12 months and can be treated with local procedures. It aims to see whether the study treatment can improve outcomes compared with standard care for people with a limited number of liver tumors.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.